A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone and in Combination with Durvalumab in Selected Advanced Solid Tumors

Frentzas, Sophia (Primary Chief Investigator (PCI))

Medicine Monash Health

Project: Research

Project Description

NMA HREC Reference Number: HREC/16/MH/424
NMA SSA Reference Number: SSA/18/MonH/393
Monash Health Ref: RES-18-0000261X

Status	Finished
Effective start/end date	25/03/19 → 8/10/20

Keywords

clinical trial
advanced solid tumor
phase 1 study
treatment efficacy

Clinical Trial Phase

Phase I